Hospital
Medical University Hospital Authority
Medical University Hospital Authority was paid $12.13M by Medicaid between Mar 2019 and Dec 2024, across 252 billing codes. Its largest line is 80053, Comprehensive metabolic panel — 17% of everything it billed.
33Billing provider infoMEDICAL UNIVERSITY HOSPITAL AUTHORITY
LANCASTER, SC 29720
LANCASTER, SC 29720
33aNPI1700359205assigned 01/07/2019
33bProvider typeGeneral Acute Care Hospital
28Total paid$12.13M
24GClaims550,646
24DCodes billed252
24AFirst – last monthMar 2019 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in South Carolina
Rank by total paid#27 of 115
Median peer was paid$2.47M
This provider vs. median4.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RAE, KARYN controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 82,798 | $1.50M | |
| 2020 | 83,037 | $1.72M | |
| 2021 | 94,853 | $2.20M | |
| 2022 | 108,246 | $2.56M | |
| 2023 | 99,304 | $2.57M | |
| 2024incomplete | 82,408 | $1.57M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80053 | Comprehensive metabolic panel | 17% | 30,489 | 25,561 | $2.08M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 15% | 4,010 | 1,732 | $1.85M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6.8% | 8,753 | 8,392 | $825K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 4.8% | 6,715 | 4,894 | $588K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 3.9% | 5,428 | 5,225 | $478K |
| 80048 | Basic metabolic panel (calcium, ionized) | 3.3% | 6,769 | 5,511 | $405K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.3% | 9,282 | 8,116 | $394K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.1% | 11,874 | 3,781 | $377K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.0% | 3,704 | 3,580 | $360K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 2.7% | 3,249 | 2,444 | $333K |
| 86850 | 2.5% | 2,731 | 2,582 | $300K | |
| 87070 | 2.2% | 1,022 | 934 | $262K |
240 more codes
| 81025 | 2.1% | 10,109 | $249K | |
| 99283 | Emergency room visit (moderate) | 1.9% | 20,079 | $236K |
| 36415 | Collection of venous blood by venipuncture | 1.5% | 29,504 | $176K |
| 82947 | 1.2% | 3,838 | $151K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.1% | 6,322 | $134K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 5,013 | $107K |
| 87081 | <1% | 3,184 | $101K | |
| 81001 | <1% | 17,059 | $100K | |
| 99284 | Emergency room visit (serious) | <1% | 15,366 | $94K |
| 86900 | <1% | 3,312 | $92K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,269 | $79K |
| 11043 | <1% | 206 | $75K | |
| 86710 | <1% | 982 | $74K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,673 | $72K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 89 | $72K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,857 | $69K |
| 85027 | <1% | 7,917 | $65K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,357 | $63K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,248 | $59K |
| 73130 | <1% | 915 | $57K | |
| 86901 | <1% | 2,870 | $55K | |
| 73610 | <1% | 990 | $53K | |
| 73630 | <1% | 1,130 | $51K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 501 | $49K |
| 80061 | Lipid panel | <1% | 5,061 | $48K |
| 82962 | <1% | 1,115 | $48K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,049 | $47K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 32,027 | $44K |
| 84702 | <1% | 2,383 | $42K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,302 | $42K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 84 | $41K |
| 87077 | <1% | 2,965 | $40K | |
| 99285 | Emergency room visit (most serious) | <1% | 12,095 | $40K |
| 11045 | <1% | 113 | $37K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 188 | $36K |
| 81003 | <1% | 6,201 | $34K | |
| 73030 | <1% | 759 | $34K | |
| 71045 | Radiologic examination, chest; single view | <1% | 8,651 | $34K |
| J2704 | Injection, propofol, 10 mg | <1% | 4,687 | $32K |
| 59025 | Fetal non-stress test | <1% | 2,143 | $31K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 790 | $31K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 7,486 | $30K |
| 73562 | <1% | 769 | $29K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,965 | $29K |
| 88304 | <1% | 489 | $26K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,209 | $26K |
| 93971 | <1% | 335 | $26K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,926 | $25K |
| 96376 | <1% | 2,310 | $24K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 816 | $24K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,764 | $24K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,028 | $23K |
| 95816 | <1% | 168 | $22K | |
| 82948 | <1% | 596 | $21K | |
| 87186 | <1% | 2,270 | $20K | |
| 72100 | <1% | 791 | $20K | |
| 0001A | <1% | 371 | $18K | |
| 73110 | <1% | 284 | $18K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 609 | $17K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,804 | $17K |
| 74018 | <1% | 490 | $17K | |
| 87430 | <1% | 2,682 | $16K | |
| 0002A | <1% | 317 | $16K | |
| 97597 | <1% | 758 | $15K | |
| G0378 | Hospital observation service, per hour | <1% | 6,521 | $14K |
| 87807 | <1% | 389 | $13K | |
| 84439 | <1% | 1,612 | $13K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 629 | $13K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 3,307 | $13K |
| 86780 | <1% | 794 | $12K | |
| 86803 | <1% | 1,092 | $11K | |
| 86756 | <1% | 252 | $10K | |
| 87205 | <1% | 608 | $10K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,208 | $10K |
| 87210 | <1% | 324 | $10K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 17 | $9K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 94 | $9K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 779 | $9K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,027 | $9K |
| 82607 | <1% | 1,247 | $9K | |
| 93970 | <1% | 81 | $8K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,573 | $7K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 458 | $7K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,257 | $7K |
| 85007 | <1% | 3,024 | $7K | |
| 83735 | <1% | 11,776 | $7K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,750 | $6K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 86 | $6K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,348 | $6K |
| 82728 | <1% | 515 | $6K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 151 | $5K |
| 84484 | <1% | 13,934 | $5K | |
| 73560 | <1% | 107 | $5K | |
| 86140 | <1% | 621 | $5K | |
| 74022 | <1% | 667 | $5K | |
| 73564 | <1% | 138 | $4K | |
| 76801 | <1% | 602 | $4K | |
| 0003A | <1% | 88 | $4K | |
| 12001 | <1% | 39 | $4K | |
| 83690 | <1% | 7,707 | $3K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 674 | $3K |
| 82043 | <1% | 1,194 | $3K | |
| 97162 | <1% | 973 | $3K | |
| 85610 | <1% | 8,553 | $3K | |
| 77062 | <1% | 24 | $3K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,844 | $3K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 65 | $3K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,633 | $3K |
| 87420 | <1% | 442 | $2K | |
| 87899 | <1% | 217 | $2K | |
| 73502 | <1% | 171 | $2K | |
| 82550 | <1% | 3,195 | $2K | |
| 76770 | <1% | 31 | $2K | |
| 82803 | <1% | 362 | $2K | |
| 87150 | <1% | 28 | $2K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 65 | $2K |
| 72050 | <1% | 25 | $2K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 18 | $2K |
| 76010 | <1% | 48 | $2K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 44 | $1K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,186 | $1K |
| 76830 | Ultrasound, transvaginal | <1% | 13 | $1K |
| 82951 | <1% | 83 | $1K | |
| 71250 | <1% | 56 | $1K | |
| 76641 | <1% | 23 | $1K | |
| 0011A | <1% | 25 | $1K | |
| 87040 | <1% | 4,474 | $1K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,213 | $1K |
| 0012A | <1% | 24 | $1K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 30 | $1K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,089 | $1K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,509 | $1K |
| 83540 | <1% | 472 | $1K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 484 | $1K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 37 | $1K |
| 70486 | <1% | 58 | $1K | |
| 73080 | <1% | 12 | $1K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 338 | $995.56 |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 14 | $977.85 |
| 85379 | <1% | 1,319 | $925.15 | |
| 83880 | <1% | 3,267 | $890.39 | |
| 0071A | <1% | 18 | $882.81 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,602 | $868.58 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 318 | $857.55 |
| 83605 | <1% | 4,296 | $852.28 | |
| 97163 | <1% | 304 | $817.16 | |
| 76642 | <1% | 19 | $786.28 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 681 | $772.29 |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 36 | $747.42 |
| 87088 | <1% | 856 | $740.19 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,355 | $713.59 |
| 0072A | <1% | 14 | $687.21 | |
| 97161 | <1% | 384 | $678.67 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 117 | $614.38 |
| 90686 | <1% | 69 | $611.63 | |
| 82140 | <1% | 77 | $577.41 | |
| 84153 | <1% | 29 | $572.76 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 645 | $568.30 |
| 82570 | <1% | 1,355 | $546.49 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 903 | $440.92 |
| 97165 | <1% | 41 | $419.29 | |
| 73590 | <1% | 15 | $392.92 | |
| 82270 | <1% | 130 | $392.40 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,281 | $376.73 |
| 82272 | <1% | 13 | $360.34 | |
| A9270 | Non-covered item or service | <1% | 310 | $297.80 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 51 | $285.85 |
| 85730 | <1% | 6,790 | $273.24 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,171 | $264.30 |
| 82247 | <1% | 17 | $198.99 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 73 | $167.29 |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 22 | $162.57 |
| 80320 | <1% | 1,785 | $162.31 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,292 | $147.18 |
| 87522 | Neg quan hep c or qual rna | <1% | 26 | $131.21 |
| 82077 | <1% | 635 | $101.27 | |
| 85652 | <1% | 164 | $82.96 | |
| 86762 | <1% | 476 | $54.61 | |
| 87340 | <1% | 557 | $41.86 | |
| 80197 | <1% | 35 | $36.01 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 108 | $34.55 |
| 90715 | <1% | 259 | $28.69 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 540 | $19.61 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,919 | $16.38 |
| 85651 | <1% | 417 | $15.12 | |
| 87075 | <1% | 55 | $12.20 | |
| 83615 | <1% | 228 | $8.17 | |
| 85018 | <1% | 13 | $3.20 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,994 | $0.97 |
| 84100 | 0% | 1,060 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 354 | $0.00 |
| 80143 | 0% | 119 | $0.00 | |
| 96367 | 0% | 115 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 305 | $0.00 |
| 93975 | 0% | 13 | $0.00 | |
| 80179 | 0% | 103 | $0.00 | |
| 85378 | 0% | 213 | $0.00 | |
| 82009 | 0% | 13 | $0.00 | |
| 84550 | 0% | 27 | $0.00 | |
| 84156 | 0% | 75 | $0.00 | |
| 99152 | 0% | 37 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 313 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 45 | $0.00 |
| 36600 | 0% | 36 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 49 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 13 | $0.00 |
| 83655 | 0% | 13 | $0.00 | |
| 77066 | Tomosynthesis, mammo | 0% | 24 | $0.00 |
| 87220 | 0% | 104 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 13 | $0.00 |
| 82248 | 0% | 27 | $0.00 | |
| 82805 | 0% | 31 | $0.00 | |
| 86787 | 0% | 14 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 54 | $0.00 |
| 85045 | 0% | 13 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 593 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 273 | $0.00 |
| 82746 | 0% | 164 | $0.00 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 0% | 374 | $0.00 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 428 | $0.00 |
| 80329 | 0% | 293 | $0.00 | |
| 82553 | 0% | 706 | $0.00 | |
| 82150 | 0% | 278 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 236 | $0.00 |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 0% | 12 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 13 | $0.00 |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 0% | 137 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 40 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 121 | $0.00 |
| 83550 | 0% | 183 | $0.00 | |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 13 | $0.00 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 22 | $0.00 |
| 71275 | Computed tomographic angiography, chest, with contrast material | 0% | 35 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 27 | $0.00 |
| C1769 | Guide wire | 0% | 20 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 128 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 13 | $0.00 |
| J3410 | Injection, hydroxyzine hcl, up to 25 mg | 0% | 12 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 14 | $0.00 |
| 97166 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRAE, KARYN (DIRECTOR)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.